IP Library Patent Application 11126742
Patent Application
App. No. 11/126,742

Method of preventing relapse in the abstinent substance dependent individual

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/126,742
Abstract

A method of preventing a relapse in the abstinent substance dependent person. The method involves the use of the medication Flumazenil in a spray delivery device and to teach the person to self-administer the medication by spraying the medication into either the nasal passage, the buccal mucosol membranes or the pulmonary membranes, whenever the need and the urge to relapse arises, thereby preventing relapse.

Claims (6)

1 . A method for treating a substance abuse relapse potential or likelihood in a substance abuse human while being in an abstinence mode, said method comprising the step of administering to said human an effective therapeutic amount of a medication, said administering is undertaken via a medicated spray intake into the mouth passage of said human, on as needed basis, when said human feels the immediate subjective premonition or danger of resorting back to the use of an abusive substance.

2 . The method of claim 1 , wherein said step of administering is a self-administering step.

3 . The method of claim 1 , wherein this is a wholly new use of said medication named Flumazenil.

4 . The method of claim 1 , wherein the step of administering consists of a buccal mucosal membrane spraying.

5 . The method of claim 1 , wherein the step of administering consists of a pulmonary aerosolization inhaler.

6 . The method of claim 1 , wherein said abusive substance is selected from the group consisting of: Alcohol, Benzodiazepine, Librium, Xanax, Ativan, Marijuana, Doriden, Miltown, Soma, Quaaludes, Baclofen, Neurontin, Ambien, GABA active drugs, GHB, and sedative hypnotics.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jul 29, 2022
From: GOLDMAN SACHS SPECIALTY LENDING GROUP, L.P., AS COLLATERAL AGENT
To: ONTRAK, INC. (FORMERLY KNOWN AS CATASYS, INC.)
Reel/Frame 060672/0554 →
SECURITY INTEREST Recorded Feb 10, 2020
From: HYTHIAM, INC (N/K/A CATASYS, INC.)
To: GOLDMAN SACHS SPECIALTY LENDING GROUP, L.P.
Reel/Frame 051767/0204 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INADVERTANT OMISSION OF AN ASSIGNOR ON THE ASSIGNMENT PREVIOUSLY RECORDED ON REEL 023265 FRAME 0051. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST. Recorded Sep 30, 2009
From: HALIKAS, JAMES A., M.D.; RECOVERY FROM ADDICTIONS, INC.
To: HYTHIAM, INC.
Reel/Frame 023306/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2009
From: HALIKAS, JAMES A., M.D.
To: HYTHIAM, INC.
Reel/Frame 023265/0051 →